177 related articles for article (PubMed ID: 25194992)
1. Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism.
Pilorgé L; Burrel S; Aït-Arkoub Z; Agut H; Boutolleau D
Antiviral Res; 2014 Nov; 111():8-12. PubMed ID: 25194992
[TBL] [Abstract][Full Text] [Related]
2. Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.
Neuber S; Wagner K; Goldner T; Lischka P; Steinbrueck L; Messerle M; Borst EM
J Virol; 2017 Jun; 91(12):. PubMed ID: 28356534
[TBL] [Abstract][Full Text] [Related]
3. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
Chou S
Antiviral Res; 2017 Dec; 148():1-4. PubMed ID: 29107686
[TBL] [Abstract][Full Text] [Related]
4. New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc.
Champier G; Hantz S; Couvreux A; Stuppfler S; Mazeron MC; Bouaziz S; Denis F; Alain S
Antivir Ther; 2007; 12(2):217-32. PubMed ID: 17503664
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
Chou S
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
[TBL] [Abstract][Full Text] [Related]
6. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.
Borst EM; Kleine-Albers J; Gabaev I; Babic M; Wagner K; Binz A; Degenhardt I; Kalesse M; Jonjic S; Bauerfeind R; Messerle M
J Virol; 2013 Feb; 87(3):1720-32. PubMed ID: 23175377
[TBL] [Abstract][Full Text] [Related]
7. Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections.
Gentry BG; Bogner E; Drach JC
Antiviral Res; 2019 Jan; 161():116-124. PubMed ID: 30472161
[TBL] [Abstract][Full Text] [Related]
8. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage.
Wang Y; Mao L; Kankanala J; Wang Z; Geraghty RJ
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881652
[TBL] [Abstract][Full Text] [Related]
10. Human cytomegalovirus terminase as a target for antiviral chemotherapy.
Bogner E
Rev Med Virol; 2002; 12(2):115-27. PubMed ID: 11921307
[TBL] [Abstract][Full Text] [Related]
11. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
12. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.
Goldner T; Hewlett G; Ettischer N; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
J Virol; 2011 Oct; 85(20):10884-93. PubMed ID: 21752907
[TBL] [Abstract][Full Text] [Related]
13. The human cytomegalovirus terminase complex as an antiviral target: a close-up view.
Ligat G; Cazal R; Hantz S; Alain S
FEMS Microbiol Rev; 2018 Mar; 42(2):137-145. PubMed ID: 29361041
[TBL] [Abstract][Full Text] [Related]
14. Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in
Piret J; Goyette N; Boivin G
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807919
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
16. New Insights into Human Cytomegalovirus pUL52 Structure.
Muller C; Alain S; Gourin C; Baumert TF; Ligat G; Hantz S
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452502
[TBL] [Abstract][Full Text] [Related]
17. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
Goldner T; Zimmermann H; Lischka P
Antiviral Res; 2015 Apr; 116():48-50. PubMed ID: 25637709
[TBL] [Abstract][Full Text] [Related]
19. Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir.
Lischka P; Zhang D; Holder D; Zimmermann H
Antiviral Res; 2016 Aug; 132():204-9. PubMed ID: 27345658
[TBL] [Abstract][Full Text] [Related]
20. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure.
Scheffczik H; Savva CG; Holzenburg A; Kolesnikova L; Bogner E
Nucleic Acids Res; 2002 Apr; 30(7):1695-703. PubMed ID: 11917032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]